{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:51:27Z","timestamp":1790779887203,"version":"4.1.0"},"reference-count":70,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Patients diagnosed with neurofibromatosis type 2 (NF2) are extremely likely to develop meningiomas, in addition to vestibular schwannomas. Meningiomas are a common primary brain tumor; many NF2 patients suffer from multiple meningiomas. In NF2, patients have mutations in the NF2 gene, specifically with loss of function in a tumor-suppressor protein that has a number of synonymous names, including: Merlin, Neurofibromin 2, and schwannomin. Merlin is a 70 kDa protein that has 10 different isoforms. The Hippo Tumor Suppressor pathway is regulated upstream by Merlin. This pathway is critical in regulating cell proliferation and apoptosis, characteristics that are important for tumor progression. Mutations of the NF2 gene are strongly associated with NF2 diagnosis, leading to benign proliferative conditions such as vestibular schwannomas and meningiomas. Unfortunately, even though these tumors are benign, they are associated with significant morbidity and the potential for early mortality. In this review, we aim to encompass meningiomas and vestibular schwannomas as they pertain to NF2 by assessing molecular genetics, common tumor types, and tumor pathogenesis.<\/jats:p>","DOI":"10.3390\/ijms22020690","type":"journal-article","created":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T14:28:53Z","timestamp":1610461733000},"page":"690","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4748-8010","authenticated-orcid":false,"given":"Suha","family":"Bachir","sequence":"first","affiliation":[{"name":"Department of Genetics, Cincinnati Children\u2019s Hospital, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3590-7940","authenticated-orcid":false,"given":"Sanjit","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Koehler","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8726-9269","authenticated-orcid":false,"given":"Abdelkader","family":"Mahammedi","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi N.","family":"Samy","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Zuccarello","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Schorry","sequence":"additional","affiliation":[{"name":"Department of Genetics, Cincinnati Children\u2019s Hospital, Cincinnati, OH 45229, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-1397","authenticated-orcid":false,"given":"Soma","family":"Sengupta","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Cincinnati, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis Type 2 (NF2): A Clinical and Molecular Review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.spen.2015.10.008","article-title":"Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms","volume":"22","author":"Ruggieri","year":"2015","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12253-013-9644-y","article-title":"Merlin, the NF2 gene product","volume":"19","year":"2013","journal-title":"Pathol. Oncol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-0036-1579766","article-title":"Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis","volume":"5","author":"Kresak","year":"2016","journal-title":"J. Pediatr. Genet."},{"key":"ref_5","unstructured":"Tiwari, R., and Singh, A.K. (2020). Neurofibromatosis Type 2. StatPearls, StatPearls Publishing."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1212\/WNL.0000000000003418","article-title":"Revisiting Neurofibromatosis Type 2 Diagnostic Criteria to Exclude LZTR1-Related Schwannomatosis","volume":"88","author":"Smith","year":"2017","journal-title":"Neurology"},{"key":"ref_7","unstructured":"Le, C., and Bedocs, P.M. (2020). Neurofibromatosis. StatPearls, StatPearls Publishing."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41436-018-0384-y","article-title":"Identifying the deficiencies of current diagnostic criteria for neurofibromatosis 2 using databases of 2777 individuals with molecular testing","volume":"21","author":"Evans","year":"2019","journal-title":"Genet. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","article-title":"Merlin\/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/gcc.10282","article-title":"NF2: The Wizardry of Merlin","volume":"38","author":"Xiao","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1046\/j.1523-1747.2000.00975.x","article-title":"Mutations and Allelic Loss of the NF2 Gene in Neurofibromatosis 2-Associated Skin Tumors","volume":"114","author":"Kluwe","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12563","DOI":"10.1038\/s41598-020-69074-z","article-title":"Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas","volume":"10","author":"Pemov","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2443.2001.00432.x","article-title":"Identification of the Cis-Acting Region in the NF2 Gene Promoter as a Potential Target for Mutation and Methylation-Dependent Silencing in Schwannoma","volume":"6","author":"Kino","year":"2001","journal-title":"Genes Cells"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/(SICI)1096-8628(19960906)64:4<563::AID-AJMG7>3.0.CO;2-Q","article-title":"Phenotypic Variability in Monozygotic Twins with Neurofibromatosis 2","volume":"64","author":"Baser","year":"1996","journal-title":"Am. J. Med. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jmg.2004.029504","article-title":"The Location of Constitutional Neurofibromatosis 2 (NF2) Splice Site Mutations Is Associated with the Severity of NF2","volume":"42","author":"Baser","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_16","first-page":"331","article-title":"Type of Mutation in the Neurofibromatosis Type 2 Gene (NF2) Frequently Determines Severity of Disease","volume":"59","author":"Ruttledge","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/neuonc\/noy009","article-title":"Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis","volume":"20","author":"Louvrier","year":"2018","journal-title":"Neuro Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1399-0004.2009.01315.x","article-title":"Further Genotype\u2014Phenotype Correlations in Neurofibromatosis 2","volume":"77","author":"Selvanathan","year":"2010","journal-title":"Clin. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neurad.2011.06.003","article-title":"Magnetic Resonance Imaging Features of Meningiomas in Children and Young Adults: A Retrospective Analysis","volume":"39","author":"Pinto","year":"2012","journal-title":"J. Neuroradiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","article-title":"An Update on the CNS Manifestations of Neurofibromatosis Type 2","volume":"139","author":"Coy","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1016\/j.wneu.2018.07.096","article-title":"Is NF2 a Key Player of the Differentially Expressed Gene Between Spinal Cord Ependymoma and Intracranial Ependymoma?","volume":"118","author":"Kim","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_22","first-page":"725","article-title":"The phakomatoses","volume":"13","author":"Smirniotopoulos","year":"1992","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.wneu.2018.08.019","article-title":"Towards Molecular Classification of Meningioma: Evolving Treatment and Diagnostic Paradigms","volume":"119","author":"Proctor","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/2018.2.FOCUS1849","article-title":"Clinical potential of meningioma genomic insights: A practical review forneurosurgeons","volume":"44","author":"Karsy","year":"2018","journal-title":"Neurosurg. Focus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"803820","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.21037\/cco.2017.05.02","article-title":"Classification of meningiomas-advances and controversies","volume":"6","author":"Harter","year":"2017","journal-title":"Chin. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/jnnp-2019-322257","article-title":"Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: An individual patient data meta-analysis","volume":"91","author":"Mirian","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/neuonc\/nos129","article-title":"Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: Clinical, radiological, and molecular features","volume":"14","author":"Goutagny","year":"2012","journal-title":"Neuro Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"ref_32","first-page":"1","article-title":"Genomic landscape of high-grade meningiomas","volume":"2","author":"Bi","year":"2017","journal-title":"NPJ Genom. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2017.07.009","article-title":"Altered expression of E-Cadherin-related transcription factors indicates partial epithelial-mesenchymal transition in aggressive meningiomas","volume":"380","author":"Wallesch","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/onc.2015.125","article-title":"Role of Merlin\/NF2 inactivation in tumor biology","volume":"35","author":"Petrilli","year":"2016","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/neuonc\/noy046","article-title":"EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma","volume":"20","author":"Angus","year":"2018","journal-title":"Neuro Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00401-013-1093-x","article-title":"Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations","volume":"125","author":"Reuss","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-013-1187-5","article-title":"AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry","volume":"126","author":"Sahm","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/neuonc\/nov316","article-title":"Oncogenic PI3K mutations are as common asAKT1andSMOmutations in meningioma","volume":"18","author":"Abedalthagafi","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3171\/2015.6.JNS15591","article-title":"Genomic landscape of intracranial meningiomas","volume":"125","author":"Bi","year":"2016","journal-title":"J. Neurosurg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11060-010-0339-x","article-title":"Meningiomas and neurofibromatosis","volume":"99","author":"Goutagny","year":"2010","journal-title":"J. Neuro Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4132\/jptm.2019.11.05","article-title":"Molecular characteristics of meningiomas","volume":"54","author":"Lee","year":"2020","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"068","DOI":"10.1055\/s-0033-1333621","article-title":"Communicating Hydrocephalus and Vestibular Schwannomas: Etiology, Treatment, and Long-Term Follow-Up","volume":"74","author":"Zeitouni","year":"2013","journal-title":"J. Neurol. Surg. Part B Skull Base"},{"key":"ref_44","first-page":"690","article-title":"Incidence of vestibular schwannoma in Denmark, 1977\u20131995","volume":"21","author":"Howitz","year":"2000","journal-title":"Am. J. Otol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1212\/01.WNL.0000163982.78900.AD","article-title":"Diagnostic criteria for schwannomatosis","volume":"64","author":"MacCollin","year":"2005","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.mao.0000180484.24242.54","article-title":"The Molecular Biology of Vestibular Schwannomas: Dissecting the Pathogenic Process at the Molecular Level","volume":"27","author":"Neff","year":"2006","journal-title":"Otol. Neurotol."},{"key":"ref_47","first-page":"515","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nat. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A novel Moesin-, Exrin-, Radixin-like gene is a candidate for the neurofibromatosis 2 tumor-suppressor","volume":"72","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/hmg\/3.3.413","article-title":"Exon scanning for mutation of the NF2 gene in schwannomas","volume":"3","author":"Jacoby","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"ref_50","first-page":"189","article-title":"Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas","volume":"98","author":"Welling","year":"1996","journal-title":"Qual. Life Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/00129492-200209000-00022","article-title":"cDNA Microarray Analysis of Vestibular Schwannomas","volume":"23","author":"Welling","year":"2002","journal-title":"Otol. Neurotol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/humu.20317","article-title":"The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene","volume":"27","author":"Baser","year":"2006","journal-title":"Hum. Mutat."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJM198803173181106","article-title":"Neurofibromatosis 2 (bilateral acoustic neurofibromatosis)","volume":"318","author":"Martuza","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/hmg\/7.13.2051","article-title":"Mosaicism in sporadic neurofibromatosis 2 patients","volume":"7","author":"Kluwe","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1097\/MAO.0000000000001932","article-title":"Next Generation Sequencing of Sporadic Vestibular Schwannoma: Necessity of Biallelic NF2 Inactivation and Implications of Accessory Non-NF2 Variants","volume":"39","author":"Carlson","year":"2018","journal-title":"Otol. Neurotol."},{"key":"ref_56","first-page":"529","article-title":"Germ-line mutations in the neurofibromatosis 2 gene: Correlations with disease severity and retinal abnormalities","volume":"59","author":"Parry","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1083\/jcb.200703010","article-title":"Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin","volume":"177","author":"Curto","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/hmg\/ddl021","article-title":"Schwannomin inhibits tumorigenesis through direct interaction with the eukaryotic initiation factor subunit c (eIF3c)","volume":"15","author":"Scoles","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.1038\/sj.onc.1208633","article-title":"The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity","volume":"24","author":"Ryu","year":"2005","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"18200","DOI":"10.1073\/pnas.0405971102","article-title":"Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L","volume":"101","author":"Rong","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"30265","DOI":"10.1074\/jbc.M312083200","article-title":"Merlin, a Tumor Suppressor, Interacts with Transactivation-responsive RNA-binding Protein and Inhibits Its Oncogenic Activity","volume":"279","author":"Lee","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.bbrc.2005.12.122","article-title":"Merlin inhibits growth hormone-regulated Raf\u2013ERKs pathways by binding to Grb2 protein","volume":"340","author":"Lim","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","article-title":"Merlin\/Neurofibromatosis Type 2 Suppresses Growth by Inhibiting the Activation of Ras and Rac","volume":"67","author":"Morrison","year":"2007","journal-title":"Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1038\/sj.onc.1208110","article-title":"Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2","volume":"23","author":"Wiederhold","year":"2004","journal-title":"Oncogene"},{"key":"ref_65","first-page":"3883","article-title":"Preclinical Evaluation of Combined Targeted Approaches in Malignant Rhabdoid Tumors","volume":"36","author":"Moreno","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41467-017-00346-5","article-title":"Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development","volume":"8","author":"Vitte","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/neuonc\/noz002","article-title":"Preclinical assessment of MEK1\/2 inhibitors for neurofibromatosis type 2\u2013associated schwannomas reveals differences in efficacy and drug resistance development","volume":"21","author":"Fuse","year":"2019","journal-title":"Neuro Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Pe\u0107ina-\u0160laus, N., Kafka, A., and Lechpammer, M. (2016). Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling. Cancers, 8.","DOI":"10.3390\/cancers8070067"},{"key":"ref_70","first-page":"1010428317705791","article-title":"Genetic changes of MLH1 and MSH2 genes could explain constant findings on microsatellite instability in intracranial meningioma","volume":"39","author":"Kafka","year":"2017","journal-title":"Tumor Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/690\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:10:14Z","timestamp":1760159414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22020690"],"URL":"https:\/\/doi.org\/10.3390\/ijms22020690","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]}}}